MedTrace Logo

Sleep, Diabetic Retinopathy and Melatonin

NCT04547439 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-04-21

No results posted yet for this study

Summary

This study explores the use of melatonin in patients with diabetic retinopathy

Conditions

Interventions

DRUG

Melatonin

Melatonin 3 mg will be taken nightly for 8 weeks

OTHER

Placebo

Placebo will be given nightly for 8 weeks

Sponsors & Collaborators

  • University of Chicago

    collaborator OTHER

  • University of Illinois at Chicago

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-03
Primary Completion
2026-02-02
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04547439 on ClinicalTrials.gov